Purpose: To investigate current pieces of evidence on Qishen Yiqi drop pill (QSYQ) in coronary heart disease (CHD). Methods: All systematic reviews (SRs) and meta-analyses (Mas) on QSYQ for CHD were collected by searching six databases and evaluated using the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2). The grading of recommendations assessment, development, and evaluation (GRADE) system was applied to assess the quality of outcomes. Results: Five SRs/MAs were analyzed and twenty-four outcome indicators were reported. The AMSTAR 2 revealed that 3 (12.5 %) of the outcome indicators were of moderate quality, 6 (25 %) were of low quality, and 15 (62.5 %) were of deficient quality. Five SRs/MAs (80 %) described adverse reactions, with two reporting no significant adverse reactions and two reporting minor adverse reactions (p > 0.05). Conclusion: Combining QSYQ with conventional therapy improves CHD patients' electrocardiogram and overall health outcomes. Future high-quality clinical trials and standardized study methods are needed to further investigate the safety of QSYQ.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: